Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hem...

Descripción completa

Detalles Bibliográficos
Autores principales: Iula, Rossella, De Novellis, Danilo, Trastulli, Fabio, Della Pepa, Roberta, Fontana, Raffaele, Carobene, Angela, Di Perna, Maria, D’Ambrosio, Alessandro, Romano, Martina, Leone, Aldo, De Fazio, Laura, Fiumarella, Alfonso, Gaeta, Giuseppe, Marafioti, Violetta, Barbato, Serafina, Palmieri, Salvatore, Rocco, Stefano, Serio, Bianca, Califano, Catello, Pane, Fabrizio, Ferrara, Felicetto, Giudice, Valentina, Selleri, Carmine, Catalano, Lucio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705330/
https://www.ncbi.nlm.nih.gov/pubmed/36457484
http://dx.doi.org/10.3389/fonc.2022.1026251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705330/
https://www.ncbi.nlm.nih.gov/pubmed/36457484
http://dx.doi.org/10.3389/fonc.2022.1026251

Ejemplares similares